Infectious Disease Reports (Jun 2022)

A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection

  • Ana-Alicia Leonso,
  • Kyle Brown,
  • Raquel Prol,
  • Saumya Rawat,
  • Arjun Khunger,
  • Romina Bromberg

DOI
https://doi.org/10.3390/idr14030048
Journal volume & issue
Vol. 14, no. 3
pp. 446 – 452

Abstract

Read online

Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) are currently the two leading causes of death among infectious diseases. As we progress towards a “new normal”, more information is required regarding post-COVID-19 syndromes. We present a case of latent tuberculosis reactivation 3 months after a successful inpatient treatment of COVID-19. A 74-year-old female from the Philippines presented with a new left mid-lung infiltrate with worsening shortness of breath and lethargy for one week prior to admission. The clinical course of the patient deteriorated despite broad-spectrum antibiotics, diuretics, and high-dose steroid therapy requiring intubation and mechanical ventilation. Her sputum culture yielded the microbiological diagnosis of TB. Anti-tubercular medications were started and the patient had a favorable clinical outcome. Our case demonstrates that immunosuppression secondary to COVID-19 and its treatments may promote the development of an active TB infection from a latent infection. It is important to be aware of this potential increase in risk during and after a COVID-19 treatment. This is especially important in high-risk populations to ensure an early diagnosis and prompt management as well as to reduce transmission.

Keywords